CRC 1116 - Master switches in cardiac ischemia


Acute myocardial infarction (AMI) is among the most frequent cardiovascular disorders in the Western world. The Collaborative Research Centre 1116 (CRC 1116) focuses on the acute and subacute phase post AMI using preclinical approaches in standardized small and large animal models as well as clinical investigations in a multidisciplinary consortium. Aim is the identification of cardiac and systemic effector mechanisms (master switches) in the acute/subacute phase after AMI that determine the morbidity and mortality after AMI and could be used as future therapeutic targets.

AMI is the consequence of thrombotic occlusion of coronary arteries and is therefore a local cardiac event. However, the adaptation of the heart after cardiac ischemia is strongly determined by a complex crosstalk between cardiac and extracardiac cell populations, metabolic adaptation, comorbidities and ischemia-triggered systemic responses. For the development of novel therapeutic strategies it will be crucial to understand the interplay of cardiac healing responses with metabolic and systemic effector mechanisms. Because a high percentage of patients receive revascularization late “late comers” or not at all, the CRC 1116 will address both, responses to ischemia/reperfusion and permanent coronary occlusion.

Project group A (intracellular and cellular effectors) will therefore investigate new cardiac effector mechanisms. Specifically mechanisms of arrythmogenesis, cardiomyocyte dysfunction, regulation of mitochondrial function and apoptosis, new posttranslational mechanisms, cardioprotective signaling, effects of acute remodeling of cardiac extracellular matrix on angiogenesis and fibroblast phenotype and underlying molecular mechanisms will be investigated. Thus project group A addresses important adaptative and maladaptative processes that are initiated in the myocardium in the acute and subacute phase post AMI.

Project group B (metabolic and systemic effectors) addresses relevant metabolic effector mechanisms and systemic crosstalk after AMI in an attempt to understand AMI as a systemic disease. To achieve this, the CRC 1116 focuses on type 2 diabetes mellitus (T2DM) and associated metabolic disorders such as non-alcoholic fatty liver, insulin resistance, prediabetes as well as effects of visceral and epicardiac adipose tissue. In addition to metabolic effector mechanisms, the contribution of immune mechanisms, clinical relevant comorbidities, such as anemia and mechanisms of remote cardiac conditioning will be analyzed.

In the long-term the CRC 1116 aims to identify new targets for improving the prognosis of patients after AMI and to allow stratification of therapeutic strategies. To achieve this long-term goal the focus of the first funding period is to identify new master switches mainly in preclinical murine models. Subsequent experiments will be designed to elucidate the effect of relevant comorbidities. Large animal models and clinical studies will provide insight into the translational value of the candidate mechanisms and targets.

Latest News

Sidney & Joan Pestka Graduate & Post-Graduate Award goes to Erika Engelowski

The Collaborative Research Centre 1116 congratulates Erika Engelowski on receiving the Sidney & Joan Pestka Graduate Award.  Erika is a PhD student of Prof. Dr. Jürgen Scheller's at the Institute of Biochemistry

Annette Kronenbitter has been awarded her PhD!

On the 13th July Annette Kronenbitter was awarded her PhD with a magna cum laude. The title of her thesis is "Altered sarcomere function and myocyte calcium cycling in the remote myocardium after myocardial infarction". 

Caffeine from Four Cups of Coffee Protects the Heart and Vessels with the Help of Mitochondria

Caffeine consumption has been associated with lower risks for multiple diseases, including type II diabetes, heart disease, and stroke, but the mechanism underlying these protective effects has been unclear.

Team Building IRTG1902 and SFB1116 on the water

The doctoral researchers of the research training groups enjoyed a team building event on lake Unterbach. In the hot weather the time on the lake was a welcome break from the Lab. The 5-person canoes provided a perfect opportunity to g

Neu eingerichtetes Eltern-Kind-Zimmer des SFB 1116 eröffnet!

Ab sofort steht den Mitarbeiterinnen und Mitarbeitern des SFB 1116 der neu eingerichtete Eltern-Kind-Raum im Institut für Pharmakologie und Klinische Pharmakologie zur Verfügung.

Das Eltern-Kind-Zimmer wurde in Zusammenarbeit mit Fra

Spokesperson Collaborative Research Centre 1116

Prof. Dr. rer. nat. Jens W. Fischer

Institut für Pharmakologie und Klinische Pharmakologie Universitätsstr. 1 40225 Düsseldorf
Phone +49 211 81-12500
Fax +49 211 81-14781
Responsible for the content: E-MailRedaktionsteam SFB 1116